UBS Upgrades Medpace Holdings to Neutral, Raises Price Target to $673

Benzinga · 1d ago
UBS analyst Kevin Caliendo upgrades Medpace Holdings (NASDAQ:MEDP) from Sell to Neutral and raises the price target from $405 to $673.